← Back to all trials
Not Yet Recruiting
NCT07920159
Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer
Conditions: High-grade Serous Ovarian Cancer
Sex: Female
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 76
Sponsor: Anhui Provincial Hospital
Summary
Patients with advanced high-grade serous ovarian cancer who underwent primary cytoreductive surgery and received adjuvant chemotherapy with paclitaxel plus carboplatin were included. CA125 levels were dynamically monitored within 100 days post-surgery, and the KELIM value was calculated to identify patients at high risk of recurrence with a KELIM \< 1.
Eligibility Criteria
Inclusion Criteria:
1. Subjects voluntarily participate in the study, provide written informed consent, and are able to comply with the study requirements.
2. Histologically confirmed primary high-grade serous ovarian cancer (HGSOC) and receipt of primary cytoreductive surgery.
3. Age ≥18 years.
4. FIGO stage III-IV disease.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
6. KELIM value \3 months.
8. Adequate major organ function, as defined by all of the following criteria: absolute neutrophil count (ANC) ≥1.5 × 10⁹/L; platelet count ≥80 × 10⁹/L; hemoglobin ≥80 g/L; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \
Source: ClinicalTrials.gov (NCT07920159). StuddyBuddy aggregates publicly available trial information.
